Sionna Therapeutics (SION) Income towards Parent Company (2024 - 2026)

Sionna Therapeutics has disclosed Income towards Parent Company across 3 years of filings, most recently posting -$26.8 million for Q1 2026.

• Income towards Parent Company for Q1 2026 came in at -$26.8 million, down 60.75% year-over-year; the trailing twelve-month figure through Mar 2026 was -$85.8 million (down 28.01% YoY), and the FY2025 annual result was -$75.7 million, down 21.32% from the prior year.
• Income towards Parent Company came in at -$26.8 million for Q1 2026 at Sionna Therapeutics, down from -$20.4 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of -$8.7 million in Q2 2024 to a low of -$26.8 million in Q1 2026.
• The 3-year median for Income towards Parent Company is -$18.2 million (2025), against an average of -$18.3 million.
• Peak annual rise in Income towards Parent Company reached 20.61% in 2025, while the deepest fall reached 109.02% in 2025.
• Sionna Therapeutics' Income towards Parent Company stood at -$16.0 million in 2024, then fell by 27.64% to -$20.4 million in 2025, then plunged by 31.01% to -$26.8 million in 2026.
• The last three Income towards Parent Company figures came in at -$26.8 million (Q1 2026), -$20.4 million (Q4 2025), and -$20.3 million (Q3 2025), per Business Quant data.